Trial · NCT02612129
Adverse events438
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 438
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Abdominal Pain Upper | Gastrointestinal disorders | Arimoclomol Single PK Dose | 1 | 28 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Arimoclomol (12-month Double-blind Phase) | 1 | 34 | |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Placebo (12-month Double-blind Phase) | 0 | 16 | |
| other | Pyrexia | General disorders | Arimoclomol Single PK Dose | 1 | 28 | |
| other | Pyrexia | General disorders | Arimoclomol (12-month Double-blind Phase) | 6 | 34 | |
| other | Pyrexia | General disorders | Placebo (12-month Double-blind Phase) | 3 | 16 | |
| other | Drug Hypersensitivity | Immune system disorders | Arimoclomol Single PK Dose | 1 | 28 | |
| other | Drug Hypersensitivity | Immune system disorders | Arimoclomol (12-month Double-blind Phase) | 1 | 34 | |
| other | Drug Hypersensitivity | Immune system disorders | Placebo (12-month Double-blind Phase) | 0 | 16 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Arimoclomol Single PK Dose | 1 | 28 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Arimoclomol (12-month Double-blind Phase) | 6 | 34 | |
| other | Upper Respiratory Tract Infection | Infections and infestations | Placebo (12-month Double-blind Phase) | 1 | 16 | |
| other | Rash | Skin and subcutaneous tissue disorders | Arimoclomol Single PK Dose | 1 | 28 | |
| other | Rash | Skin and subcutaneous tissue disorders | Arimoclomol (12-month Double-blind Phase) | 1 | 34 | |
| other | Rash | Skin and subcutaneous tissue disorders | Placebo (12-month Double-blind Phase) | 1 | 16 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arimoclomol Single PK Dose | 0 | 28 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arimoclomol (12-month Double-blind Phase) | 1 | 34 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Placebo (12-month Double-blind Phase) | 0 | 16 | |
| other | Phimosis | Congenital, familial and genetic disorders | Arimoclomol Single PK Dose | 0 | 28 | |
| other | Phimosis | Congenital, familial and genetic disorders | Arimoclomol (12-month Double-blind Phase) | 1 | 34 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02612129/events